Our Science – Hodge Website
James W. Hodge, Ph.D., MBA
Selected Publications |
 |
| 1)
Huang J, Jochems C, Anderson AA, Talaie T, Jales A, Madan RA, Hodge JW, Tsang KY, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J. Soluble CD27-pool in humans may contribute to T-cell activation and tumor immunity. J Immunol. 2013. In Press. [Journal] |
|
| 2)
Singh N, Hodge JW, Madan R, Gulley JL. Shurin MR, Umansky V, Malyguine A, eds. Combining vaccines with therapies that render tumor cells more susceptible to immune mediated killing. In: The Tumor Immunoenvironment. Dordrecht: Springer Science+Business Media; 2013. p. 621-642 [Book Chapter] |
|
| 3)
Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang K, Ferrone S, Gameiro SR. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int. J. Cancer. [Epub ahead of print], 2013. [Journal] |
|
| 4)
Campbell CT, Gulley JL, Oyelaran O, Hodge JW, Schlom J, Gildersleeve JC. Serum Antibodies to Blood Group A Predict Survival on PROSTVAC-VF. Clin. Cancer Res. 19: 1290-9, 2013. [Journal] |
|
| 5)
Hodge JW, Sharp HJ, Gameiro SR. Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation. Cancer Biother. Radiopharm. 27: 12-22, 2012. [Journal] |
|
| 6)
Heery CR, Hodge JW, Gulley JL. Combining radiation and therapeutic cancer vaccines: a synergistic approach. Breast Cancer Management. 1: 325-335, 2012. [Journal] |
|
| 7)
Gameiro SR, Caballero JA, Hodge JW. Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing. Cancer Biother. Radiopharm. 27: 23-35, 2012. [Journal] |
|
| 8)
Kwilas AR, Donahue RN, Bernstein MB, Hodge JW. In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer. Front Oncol. 2: 104, 2012. [Journal] |
|
| 9)
Schlom J, Hodge JW. Introduction: therapeutic cancer vaccines. Semin. Oncol. 39: 243-4, 2012. [Journal] |
|
| 10)
Hodge JW, Ardiani A, Farsaci B, Kwilas AR, Gameiro SR. The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Semin. Oncol. 39: 323-39, 2012. [Journal] |
|
| Click Here to View Expanded Bibliography. |
This page was last updated on 4/29/2013.
